drugset / Trial / NCT06616571

Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints

NCT06616571

Phase 4 Recruiting 336 enrolled Qilu Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this real-world study is to compare the efficacy and safety of QL0605 administered 24 hours and 48 hours after chemotherapy in breast cancer patients.

Timeline

Start
2024-09-19
Primary completion
2025-12-30
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegfilgrastim Protein / enzyme biologic Subcutaneous